After enriching by prospectively genetic and pharmacological testing, we believe that the combination of HGF/MET-targeted agents (i.e., tivantinib) with conventional chemotherapeutics or molecularly targeted agents (i.e., EGFR, VEGFR, and PI3K/Akt targeting agents) may provide the optimal personalized treatment regimens for advanced HCC patients. The gene discussed is KDR; the disease is hepatocellular carcinoma.